Spartalizumab
Based on 1 Customer Validation
Spartalizumab is a humanized PD-1 IgG4 monoclonal antibody, with a Kd of 0.83 nM for human PD-1 and a Kd of 0.93 nM for cynomolgus monkey PD-1. Spartalizumab binds to PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2. Spartalizumab induces increased IFNγ release. Spartalizumab can be used in the research of anaplastic thyroid carcinoma (ATC) and neuroendocrine neoplasms (NENs).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.50%
- CAS No.: 1935694-88-4
- Masse moléculaire:143.14 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
PDCD1/PD-1/CD279
In Vitro
Spartalizumab binds to human and cynomolgus monkey PD-1 with mean Kd values of 0.83 nM and 0.93 nM, respectively, and does not bind to mouse PD-1[1].
Spartalizumab (incubated at 4°C for 4 h) inhibits the binding of PD-1 to PD-L1 and PD-L2 in PD-1-expressing murine 300.19 cells, with IC50 values of 0.9 nM and 1.3 nM, respectively[1].
Spartalizumab induces a concentration-dependent increase in IFNγ release in mixed lymphocyte reaction assays[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized PD-1 Protein, Human can bind Spartalizumab. The EC50 for this effect is 14.84 ng/mL. -
Flow cytometric analysis of 1X106 10 ng/mL PMA and 1 μg/mL Ionomycin co-stimulated Jurkat cells(24h) with Spartalizumab (HY-P9972, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Product Details
-
CAS No. 1935694-88-4
-
Accession Q15116
-
Synonyms PDR001
-
Masse moléculaire 143.14 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG4 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG4 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Pureté
99.50%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Livraison
Shipping with dry ice.
Pureté et documentation
Références
[1]. Naing A, et al. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer. 2020 Mar;8(1):e000530. [Content Brief]
[2]. Capdevila J, et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020;38(23):2620-2627. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)